Patents by Inventor Hans-Georg Rammensee

Hans-Georg Rammensee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS
    Publication number: 20190284235
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 19, 2019
    Inventors: Hans-Georg RAMMENSEE, Juliane WALZ, Daniel Johannes KOWALEWSKI, Stefan STEVANOVIC, Simon WALZ
  • NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS
    Publication number: 20190284236
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 19, 2019
    Inventors: Hans-Georg Rammensee, Juliane Walz, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)
    Publication number: 20190284233
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: May 24, 2019
    Publication date: September 19, 2019
    Inventors: Juliane WALZ, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
  • Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
    Publication number: 20190275130
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: March 29, 2019
    Publication date: September 12, 2019
    Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
  • Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers
    Patent number: 10377797
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 13, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Juliane Stickel, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
  • Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
    Patent number: 10364271
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 30, 2019
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
    Patent number: 10286052
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: May 14, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Johannes Kowalewski, Claudia Berlin
  • NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS
    Publication number: 20190077832
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 14, 2019
    Inventors: Hans-Georg Rammensee, Juliane Stickel, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)
    Publication number: 20190055286
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 2, 2018
    Publication date: February 21, 2019
    Inventors: Juliane Walz, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
  • Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers
    Patent number: 10196422
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Juliane Stickel, Daniel Kowalewski, Stefan Stevanovic, Simon Walz
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)
    Publication number: 20190002497
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: September 10, 2018
    Publication date: January 3, 2019
    Inventors: Juliane STICKEL, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
  • Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
    Patent number: 10167317
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 1, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Stickel, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
    Patent number: 10144763
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Stickel, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
    Publication number: 20180311330
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 1, 2018
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Johannes Kowalewski, Claudia Berlin
  • PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS
    Publication number: 20180291083
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 10, 2018
    Publication date: October 11, 2018
    Inventors: Juliane Sarah WALZ, Daniel KOWALEWSKI, Markus LÖFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
  • PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
    Publication number: 20180291082
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 10, 2018
    Publication date: October 11, 2018
    Inventors: Juliane Sarah WALZ, Daniel KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
  • Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
    Patent number: 10064924
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Kowalewski, Claudia Berlin
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)
    Publication number: 20180244722
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Inventors: Juliane STICKEL, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
  • Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
    Publication number: 20180222961
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 9, 2018
    Inventors: Heiko Schuster, Janet Peper, Kevin Röhle, Philipp Wagner, Hans-Georg Rammensee
  • Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
    Patent number: 10000533
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: June 19, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Stickel, Daniel Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic